{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:32:50Z","timestamp":1761964370434},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T00:00:00Z","timestamp":1334534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>A prospective multicenter Phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study was performed to examine the efficacy and safety of imatinib therapy in newly diagnosed Japanese patients with chronic\u2010phase <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>. Patients were scheduled to receive imatinib 400\u00a0mg daily. Plasma imatinib concentrations were measured by liquid chromatography\u2013tandem mass spectrometry. In 481 evaluable patients, estimated 7\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) and event\u2010free survival (<jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>) at a median follow\u2010up of 65\u00a0months were 93% and 87%, respectively. Because imatinib dosage was reduced in many patients due mainly to adverse events, subgroup analysis was performed according to the mean daily dose during the first 24\u00a0months of treatment: \u2265360\u00a0mg (400\u2010mg group; <jats:italic>n<\/jats:italic>\u00a0=\u00a0294), 270\u2013359\u00a0mg (300\u2010mg group; <jats:italic>n<\/jats:italic>\u00a0=\u00a090) and &lt;270\u00a0mg (200\u2010mg group; <jats:italic>n<\/jats:italic>\u00a0=\u00a067). There were no significant differences in <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content> between the 300\u2010 and 400\u2010mg groups; however, cumulative rates of complete cytogenetic and major molecular responses differed significantly between the two groups. There were no significant differences in mean imatinib trough levels between these two groups for the patients in whom trough levels had been measured. Survival and efficacy in the 200\u2010mg group were markedly inferior to the former two groups. These results suggest that, although a daily dose of 400\u00a0mg imatinib is associated with better outcomes, 300\u00a0mg imatinib may be adequate for a considerable number of Japanese patients who are intolerant to 400\u00a0mg imatinib. Blood level monitoring would be useful to determine the optimal dose of imatinib. (<jats:italic>Cancer Sci<\/jats:italic> 2012; 103: 1071\u20131078)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2012.02253.x","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T18:32:30Z","timestamp":1330194750000},"page":"1071-1078","source":"Crossref","is-referenced-by-count":36,"title":["Long\u2010term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study"],"prefix":"10.1111","volume":"103","author":[{"given":"Kazunori","family":"Ohnishi","sequence":"first","affiliation":[{"name":"Oncology Center Hamamatsu University School of Medicine Hamamatsu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology Chiba University Hospital Chiba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Nihon University School of Medicine Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City University Medical Center Yokohama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Division of Hematology Jichi Medical University Hospital Shimotsuke"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Cellular Transplantation Biology Kanazawa University Graduate School of Medical Science Kanazawa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Tokyo Medical University Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotoshi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute for Artificial Organs, Transplantation &amp; Gene Therapy Sapporo Hokuyu Hospital Sapporo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hematology Tokyo Women's Medical University School of Medicine Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiharu","family":"Yagasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology International Medical Center Saitama Medical University Hidaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology Kinki University Faculty of Medicine Osakasayama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[{"name":"Division of Oncology and Hematology Department of Internal Medicine The Jikei University School of Medicine Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences Nagasaki"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[{"name":"Hematology Division Japanese Red Cross Nagoya Daiichi Hospital Nagoya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Science Kanazawa University Graduate School of Medical Science Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Japan Adult Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004325"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0263-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402392"},{"key":"e_1_2_7_12_1","first-page":"481","article-title":"Correlation of quantification of major bcr\u2010abl mRNA between TMA (transcription mediated amplification) method and real\u2010time quantitative PCR","volume":"50","author":"Yagasaki F","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(01)00611-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0326-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00982.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21274"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0621-x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-161737"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2010.98"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"500S","DOI":"10.1200\/jco.2010.28.15_suppl.6554","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients","volume":"28","author":"Soverini S","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2012.02253.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2012.02253.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:23:26Z","timestamp":1700601806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2012.02253.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1349-7006.2012.02253.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02253.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"type":"print","value":"1347-9032"},{"type":"electronic","value":"1349-7006"}],"subject":[],"published":{"date-parts":[[2012,4,16]]}}}